Showing 5531-5540 of 7686 results for "".
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα
- More Photos of Patients with Psoriasis Needed in Studieshttps://practicaldermatology.com/news/more-photos-of-patients-with-psoriasis-needed-in-studies/2462142/As the adage goes, "a picture is worth a thousand words," yet most researchers don't include photos of patients with psoriasis in scientific articles. This is the main finding from a new study out of the University of Gothenburg in Sweden and the University of Copenha
- New Deadline: Allergan Aesthetics, University Lab Partners Launch Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://practicaldermatology.com/news/news-you-can-use-allergan-aesthetics-university-lab-partners-launch-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups/2462091/University Lab Partners (ULP) and Allergan Aesthetics are launching the Golden Passport pitch competition for aesthetic startups. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including scientific and business lea
- Scientists 3D-print Hair Follicles in Lab-grown Skinhttps://practicaldermatology.com/news/scientists-3d-print-hair-follicles-in-lab-grown-skin/2462137/Scientists at Rensselaer Polytechnic Institute have 3D-printed hair follicles in human skin tissue cultured in the lab. This marks the first time that researchers have used the technology to generate hair follicles. The findings appear in
- AI In Action: Almirall, Absci AI Drug Discovery Partner to Rapidly Develop New treatments for Skin Diseaseshttps://practicaldermatology.com/news/ai-in-action-almirall-absci-ai-drug-discovery-partner-to-rapidly-develop-new-treatments-for-skin-diseases/2462135/Almirall S.A. and Absci Corporation, a generative artificial intelligence (AI) drug creation company, are teaming up to develop and commercialize AI-designed therapeutics to treat dermatological diseases. The partnership combines Absci’s Integrated Drug C
- Unmet Needs in Dermatology: NFX-179 Topical Gel May Shrink Cutaneous Neurofibromas in NF1 Patientshttps://practicaldermatology.com/news/unmet-needs-in-dermatology-nfx-179-topical-gel-may-shrink-cutaneous-neurofibromas-in-nf1-patients/2462134/NFX‑179 Gel produced a statistically significant improvement over vehicle in the shrinkage of cutaneous neurofibromas in people with neurofibromatosis type 1 (NF1), according to positive topline results from a Phase 2b clinical trial. Cutaneous neurofibromas (cNFs) appear in over 9
- ACAAI News: 72% of AD Patients Report Poor Mental Health for 1-10 Days in the Past Monthhttps://practicaldermatology.com/news/acaai-news-72-of-ad-patients-report-poor-mental-health-for-1-10-days-in-the-past-month/2462129/Folks with atopic dermatitis (AD) are more likely to report poor mental health than their counterparts without the inflammatory skin condition, new research shows. The study, which was presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientif
- Is Lower Extremity Lymphedema a Risk for Skin Cancer?https://practicaldermatology.com/news/is-lower-extremity-lymphedema-a-risk-for-skin-cancer/2462127/Patients with lymphedema may have twice the risk of developing basal cell carcinomas and squamous cell carcinomas on the lower extremities than their counterparts without lymphedema, according to a retrospective study published in the November 2023 issue of the Mayo Clinic Proceedings.&n
- TNF Blockers Are Not Associated With Poor Pregnancy Outcomeshttps://practicaldermatology.com/news/tnf-blockers-are-not-associated-with-poor-pregnancy-outcomes/2462122/Continuing tumor necrosis factor (TNF) inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy, according to research presented at ACR Convergence 2023, the American College of Rheumatology&r
- ACR Update: TAK-279 Shows Promise in Phase 2b Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/acr-update-tak-279-shows-promise-in-phase-2b-psoriatic-arthritis-study/2462119/Takeda's investigational tyrosine kinase 2 (TYK2) inhibitor TAK-279 showed significant efficacy in patients with active psoriatic arthritis, according to Phase 2b data slated to be presented at the American College of Rheumatology's (ACR) annual meeting in San Diego, California.